drugset / Trial / NCT05170659
Expanded Access for Relatlimab
Summary
This is an expanded access designed to provide access to Relatlimab for eligible participants.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Relatlimab | Monoclonal antibody | — | — |
Indications
No indication recorded.